Trial Profile
BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With Single de Novo Coronary Artery Lesions - II.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Everolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BIOFLOW-II
- Sponsors BIOTRONIK
- 01 Sep 2023 Results of pooled analysis from BIOFLOW-II, -IV, and -V assessing the outcomes of patients with higher atherothrombotic risk (H-ATR) versus lower atherothrombotic risk (L-ATR) undergoing percutaneous coronary intervention (PCI) with either bioresorbable-polymer sirolimus-eluting stent (BP-SES) or durable-polymer everolimus-eluting stent (DP-EES published in the Clinical Research in Cardiology.
- 01 Jul 2022 Results comparing the clinical outcomes after complex PCI with a bioresorbable-polymer sirolimus-eluting stent (BP-SES) versus a durable-polymer everolimus-eluting stent (NCT01356888, NCT01939249, NCT02389946) published in the Clinical Research in Cardiology
- 01 Nov 2021 Results of pooled analysis (n=3717) assessing the safety and efficacy of a bioresorbable polymer sirolimus eluting stent system (BP-SES; Orsiro) compared to a durable polymer everolimus eluting stent system (DP-EES; Xience) in the pooled population as well as in subgroups from BIOFLOW-II (NCT01356888), -IV (NCT01939249), and -V (NCT02389946) as well as the all comers registry BIOFLOW-III (NCT01553526) studies, published in the Catheterization and Cardiovascular Interventions.